English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psychedelic Water Review: Does Kava Really Replace Your Evening Drink?
A friend of mine cracked open one of these cans at a backyard dinner last summer and someone immediately asked if she was tripping. She wasn’t. She was drinking what looked like a hard seltzer, was called Psychedelic Water, and contained roughly zero psychedelics. The name does a lot of heavy lifting — some of it useful, some of it misleading. I spent about a month using it the way the marketing suggests: as the thing in my hand at gatherings where everyone else was reaching for a margarita. I’m not strictly sober, I just have terrible hangovers and a low tolerance for the slow social erosion that comes with regular drinking. So this counted as a real experiment, not a stunt. Here’s what I learned about the drink, the ingredients, and the broader trend it rides on — including how it overlaps (and doesn’t) with the actual world of psychedelics and plant medicine. The headline ingredient is kava — a root from the South Pacific that islanders have used in social and ceremonial settings for centuries. Traditional kava is prepared by pounding or grinding the root and mixing it with water until you have something resembling muddy dishwater that tastes, frankly, the way it looks. The canned version is a much gentler product: kava extract, damiana leaf (a mild relaxant with a long history in Central America), green-tea extract for a small caffeine lift, and flavoring. Four flavors are in rotation — hibiscus lime, blackberry yuzu, oolong orange blossom, and prickly pear. Prickly pear is the one to start with. What kava does in the body is sedative-adjacent. It binds to GABA receptors, which is the same general pathway alcohol and benzodiazepines use, although kava is far gentler. You feel a softening of the edges. A loosening in the shoulders. Conversation feels easier without the sloppy disinhibition booze gives you. The National Institutes of Health notes that kava supplements have shown a small effect on reducing anxiety in clinical studies — modest, but real. One thing worth flagging up front: kava has been linked in rare cases to liver injury, especially when used heavily or combined with alcohol or certain medications. If you’re on prescription meds, drink regularly, or have any liver concerns, talk to a doctor before making this a habit. The occasional can at a dinner party is a different beast than daily use. Let’s clear up the obvious confusion first. Psychedelic Water is not psychedelic. There is no LSD, no psilocybin, no DMT, no mescaline. You will not see geometric patterns. You will not have an ego-dissolution experience in your kitchen. The name is a marketing choice — provocative, memorable, and arguably useful in the way it nudges the word “psychedelic” into ordinary supermarket vocabulary, but the can itself is closer to a fancy herbal tea than to anything you’d find at an ayahuasca retreat. What it actually feels like, for me, was a soft 20-minute onset of mild calm. A faint tingle on the tongue (kava does that — it’s a quirk of the active compounds called kavalactones). A small lift in mood that didn’t spike or crash. After two cans across an evening I felt loose-jawed and content. After three I felt slightly queasy and had a dull stomach ache, so I’d say two is the practical ceiling. The most useful comparison I can give: it sits somewhere between chamomile tea and a single glass of wine on the relaxation spectrum, minus the next-day fog. I slept well. I woke up sharp. I did not text anyone something I regretted. By the modest standards of a Tuesday night, that’s a win. Nonalcoholic-beverage sales jumped roughly a third year-over-year a couple of years back, and the curve has kept climbing since. The category that used to mean O’Doul’s and grape juice now includes adaptogenic sodas, hemp-derived seltzers, functional mushroom blends, and a whole subgenre of kava drinks. Psychedelic Water is one of the louder voices in that crowd, partly because of TikTok and partly because of the name. The motivations behind sober-curious living are more varied than the wellness narrative suggests. Yes, some people are quitting for health. But just as many cite productivity, mental clarity, sleep quality, and the simple math of not wanting to feel rotten on Saturday morning. Younger drinkers are also doing it for cost — alcohol is expensive — and for the fact that they’ve grown up watching the long-term damage it does to the people around them. That last one matters more than people admit. Alcohol is a pretty effective short-term anesthetic. Take it away and a lot of stuff surfaces — restlessness, sadness, the patterns you’ve been numbing for years. Some people find that uncomfortable and circle back. Others find it’s the doorway they didn’t know they were looking for. Here’s where it gets interesting for anyone who lands on a drink like this and starts wondering what else is out there. Kava is, in the broadest sense, a plant medicine. It’s a botanical with psychoactive properties used ceremonially by an indigenous culture for generations. That puts it in the same loose family as ayahuasca, San Pedro, peyote, and the other master plants — but the family is very, very loose. Kava sedates. Ayahuasca rearranges your sense of reality for six hours and shows you the contents of your own mind. They are not the same tool. I’ve sat in a number of ayahuasca ceremonies and interviewed facilitators across Peru, Costa Rica, and the Netherlands. The thing readers most often miss is that the “psychedelic” part of psychedelics isn’t about visuals or recreation — it’s about a temporary suspension of the usual mental machinery that lets you see your patterns, your trauma, your addiction, your grief, with unusual clarity. That’s why these medicines have become a serious conversation in addiction recovery, depression treatment, and PTSD therapy. Compounds like psilocybin and ibogaine are now in late-stage clinical trials for exactly those uses. A canned kava drink will not do any of that. What it might do, honestly and usefully, is start a conversation. If you’re someone who picks up a can called Psychedelic Water at a dinner party and finds yourself curious — really curious — about what the word actually means, that curiosity is worth following. Read about the Indigenous traditions. Read the Johns Hopkins research. Talk to people who’ve done the work. Don’t confuse a beverage with a ceremony. If you’re looking for a smarter thing to hold at a party, or a wind-down drink that won’t cost you Sunday morning, this category is worth exploring and Psychedelic Water is a reasonable entry point. Go in with realistic expectations. You’re buying a mild herbal relaxant in a stylish can, not a portal to anywhere. Pay attention to how your body responds, don’t mix it with alcohol or sedatives, and skip it entirely if you’re pregnant, on liver-sensitive meds, or drinking heavily already. And if the experiment leaves you genuinely interested in what plant medicines can do at the deeper end — addiction work, trauma work, the kind of inner inventory that actually changes a life — there’s a much larger world waiting. A growing range of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here, with facilitators and traditions worth taking seriously. Start with the can if you want. Just know that the can is the beginning of the question, not the answer.
Ibogaine Aftermath: Double Vision, Insomnia, and Body Temperature Swings Explained
Three days after a flood dose, you finally try to read something on your phone and the letters won't sit still. Sleep comes in 40-minute scraps. Your hands feel hot, your feet feel like ice, and your heart seems to be reporting from another time zone. Sound familiar? If you've recently sat with ibogaine — or you're researching what the recovery actually looks like before booking a retreat — this is the conversation nobody puts on the glossy brochure. Ibogaine is one of the most powerful tools in the plant medicine and psychedelic world for breaking addiction, particularly opioid dependence. It's also one of the most physiologically demanding. The aftermath can stretch out for weeks. Knowing what's normal, what's annoying, and what's a red flag matters. Most psychedelics clear your system in hours. Ibogaine doesn't play by those rules. The active alkaloid metabolizes into noribogaine, which binds to fat tissue and slowly releases back into circulation for days — sometimes weeks. That's part of what makes ibogaine so unusual for addiction work: the afterglow has a pharmacological tail. It's also why people report odd, lingering effects long after they assumed they'd be back to baseline. Noribogaine continues to nudge serotonin, dopamine, and opioid receptors. Your nervous system, meanwhile, has just been through something closer to a controlled crisis than a typical ceremony. The autonomic system — the one that runs your heartbeat, body temperature, digestion, and sleep — takes time to recalibrate. So when people show up in forums asking about double vision, insomnia, and thermoregulation chaos, they're not imagining things. These are documented post-ibogaine experiences. Across facilitator notes, harm-reduction guides, and the people I've talked with after their retreats, three after-effects come up over and over in the first one-to-four weeks: None of these are particularly fun. Most of them resolve on their own. But they're worth understanding so you can tell ordinary recovery from something that needs attention. During the ibogaine experience itself, eyes-closed visuals are part of the territory — the rapid film-reel of memories that the medicine is famous for. Afterwards, some people notice their eyes feel uncoordinated for days. Reading is hard. Phone screens blur. Driving feels unsafe. The mechanism is ataxia — a temporary disruption in the cerebellum's coordination of fine motor movement, including the muscles that aim your eyeballs. Ibogaine is famously ataxic during the acute phase (you'll have been walked to the bathroom by a facilitator for a reason), and residual cerebellar effects can hang around. Most people see this clear up within a week or two. If it's still happening at the four-to-six-week mark, that's the point to see a neurologist rather than another forum. This one surprises people. You'd think a medicine that knocks you flat for 24 hours would leave you ready to sleep for a month. Instead, the opposite often happens. Many people report two, three, even five days of almost no sleep after a flood dose, followed by weeks of choppy, fragmented rest. Part of this is noribogaine's stimulant-like profile slowly tapering off. Part of it is that opioid withdrawal — if that's why you came to ibogaine in the first place — has its own insomnia signature that doesn't fully resolve when the acute withdrawal does. And part of it is simply that your nervous system has been turned inside out and is still finding its footing. Practical things that help: keep caffeine to a minimum, get morning sunlight on your eyes, eat real meals at regular times, avoid heavy screens before bed, and accept that sleep will be weird for a while. Magnesium glycinate at night helps some people. Melatonin is hit-or-miss after ibogaine — some find it useful, others say it makes the dreams more intense than they want. Thermoregulation is run by your hypothalamus, which sits at the intersection of the endocrine and autonomic nervous systems. Both of those systems got rattled. So it's not strange that for a few weeks, your internal thermostat seems broken. People describe sweating through sheets, then shivering in a warm room twenty minutes later. Hands and feet that won't warm up. A face that flushes for no reason. Layered clothing is your friend. So is staying well hydrated with electrolytes — sodium, potassium, magnesium — because ibogaine is hard on minerals and the residual effects can show up as temperature swings. Most after-effects fade. Some don't, and a few are genuinely dangerous. The two that demand immediate medical attention are anything cardiac and anything that looks like a prolonged QT-interval issue. Ibogaine prolongs the QT interval, which means it can predispose the heart to a specific kind of arrhythmia called torsades de pointes. This is why reputable retreats screen for cardiac risk with an EKG, magnesium and potassium bloodwork, and a careful medication review before they'll give you a dose. The risk window for QT prolongation extends well past the ceremony itself — some studies suggest two weeks or more. Get medical care immediately if, in the weeks after ibogaine, you experience: The vast majority of people who do ibogaine in a properly screened, properly supervised setting come through without any of these. The minority who run into trouble usually skipped the screening — either because they treated at home with no medical backup, or because the operation they went to wasn't actually running the tests they claimed to. This is where the booking decision really lives, in my view. Anyone can hand you a capsule. What separates a credible ibogaine provider from a sketchy one is what happens before and what happens after. Things to ask before you put a deposit down: A serious operation will have answers ready. A sketchy one will get vague, defensive, or pivot to talking about how powerful the medicine is. The medicine is powerful. That's the point. It's also why the wrapper around the medicine — the screening, the supervision, the integration — matters more than the medicine itself. Here's the thing about ibogaine specifically, as compared with ayahuasca or psilocybin: the post-acute window stretches longer because of that fat-stored noribogaine slowly trickling back into your bloodstream. Many people describe two to six weeks of feeling unusually open, emotionally permeable, sometimes raw. The cravings for the substance you came to address may be remarkably quiet. Old emotional material may keep surfacing. This is the integration window. It's a gift if you use it. Therapy appointments scheduled in advance, a support group, a sober community, daily walks, journaling — the unglamorous infrastructure of recovery — work better in this window than at any other time. People who waste it tend to find the cravings creeping back. People who use it tend to describe ibogaine as the most useful single event in their recovery, even years later. If you're still researching whether this path is right for you, take your time. Read survivor accounts, read the harm-reduction literature, talk to people who've done it. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. The strange weeks after a flood dose aren't a sign that something went wrong. Usually they're a sign that something significant happened, and your body is still catching up. Treat that body kindly. Sleep when you can. Eat real food. Keep someone you trust in the loop. And if anything feels truly off — especially anything cardiac — don't tough it out. Get checked.
Psilocybin for Depression: What a Year-Long Johns Hopkins Study Actually Found
Picture this: two psilocybin sessions, spaced a couple of weeks apart, and a year later your depression scores are still down. That's the finding making the rounds out of Johns Hopkins, and if you're someone quietly considering a psychedelic retreat for a low mood that won't lift, it's worth understanding what the research actually says — and what it carefully avoids saying. The short version is genuinely promising. The longer version, which is the one you need if you're weighing a real decision, comes with caveats that the cleaner headlines tend to skip. Let's go through both. Researchers at the Johns Hopkins Center for Psychedelic and Consciousness Research followed 24 adults with major depressive disorder after giving them two doses of psilocybin alongside supportive psychotherapy. They'd already published earlier results showing the antidepressant effect held for two months. The new paper, in the Journal of Psychopharmacology, extends that follow-up to a full twelve. The numbers are striking. Average depression scores dropped from 22.8 — squarely in the severe range — to 7.7, which sits right at the threshold of no depression at all. That's not a marginal nudge. That's the kind of shift people normally chase across years of medication trials, talk therapy, and dose adjustments. And the participants got there with two guided sessions. No serious adverse events were reported as related to the psilocybin itself. Roland Griffiths, who led the work, framed it bluntly: where standard antidepressants need to be taken every day, often indefinitely, psilocybin may be able to do the job with one or two carefully held sessions. That's a different model of treatment entirely. Depression rarely travels alone. People who land on the idea of psychedelics — ayahuasca, psilocybin, ibogaine, San Pedro, the broader family of master plants — are often dealing with some braided combination of low mood, anxiety, trauma, and addiction. The same neural ruts that keep someone reaching for a drink at 9pm keep them reaching for the same dark thought at 3am. They're not separate problems wearing different costumes. That's part of why psychedelic-assisted recovery has caught so much attention. The effect isn't symptom suppression; it's something closer to a temporary loosening of the patterns themselves. Psilocybin appears to act on serotonin pathways in a way that interrupts the looping, self-referential negativity that defines a depressive episode. For some people, that interruption is enough to climb out. For others, it opens a window — and what they do with that window matters more than the medicine. This is the part the research gestures at but doesn't shout. About a third of the study's participants started an antidepressant during the follow-up year, and roughly 40% got some form of psychotherapy. The headline isn't psilocybin alone fixes depression for a year. The honest version is psilocybin, plus integration, plus often some combination of ongoing support, produced lasting change for most of the people in this small study. Not as snappy. More accurate. Standard SSRIs work for many people, partially work for many more, and don't work at all for a stubborn minority. Even when they help, they ask for daily commitment, side effects ranging from sexual dysfunction to emotional flattening, and a wind-down period that can be genuinely miserable. Psilocybin, in this trial, looks more like a procedure than a prescription — closer in shape to a surgical intervention than to a pill bottle. Two sessions. Substantial upfront cost in time, money, and emotional bandwidth. And then, in theory, you go on with your life. David Nutt of Imperial College London, who wasn't part of the Hopkins team, made the cost-efficacy point: the upfront expense of psychedelic therapy is high, but if the effects hold, it could compete with — or beat — the lifetime cost of conventional antidepressants. That math only works if the durability holds across larger and more diverse populations than 24 carefully screened volunteers, which is exactly what late-stage trials are now investigating. Here's where I want to slow you down, because this is where the gap between a research study and a real-world retreat opens widest. The Hopkins participants didn't take psilocybin on a beach in Jamaica or a jungle lodge in Peru. They took it in a controlled clinical room, with trained therapists, after multiple preparation sessions, with structured integration afterward. The medicine was one component of a careful protocol. Strip away the protocol and you're not running the same experiment anymore — you're running a different one, with different odds. A few things worth holding in mind if you're considering a psychedelic retreat for depression or addiction: None of this is meant to dampen the genuine promise here. It's meant to put the promise in scale. Psilocybin and the broader family of plant medicines look more and more like serious tools for serious problems. Tools, though. Not magic. The person holding the tool — meaning you, the support team, the facilitator, the therapist you see afterward — still does most of the work. The Hopkins paper sits inside a much larger wave. Compass Pathways is running late-stage psilocybin trials. MDMA for PTSD has been through multi-site Phase 3 work. Ibogaine continues to draw attention for opioid dependence. Ayahuasca research, slower and messier because of the ritual context, keeps producing intriguing signals around depression, addiction, and trauma. The picture forming across all of it is consistent: when paired with thoughtful psychological support, psychedelics can produce changes that standard pharmacology has struggled to match. The catch — and there's always a catch — is that the research settings bear little resemblance to most real-world settings. Underground use, casual recreational use, and even some retreat experiences strip away the elements that the trials suggest matter most. The medicine alone is not the whole story. It might not even be the most important part of the story. If you're someone reading this with a specific decision in mind — should I book a retreat, should I try psilocybin, should I look into ayahuasca for the thing I haven't been able to shake — let the research inform you without letting the headlines stampede you. The data is encouraging. The framework around the data is what makes it work. For readers who want to take this further, a range of carefully vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Depression is patient. It waits. The good news is that the tools available for working with it are finally getting more interesting than they've been in decades. The better news is that you get to be deliberate about how you use them.
Mixing Weed and Magic Mushrooms: What Actually Happens
Ask any group of psychonauts whether they've ever lit a joint mid-mushroom trip, and most will smirk before answering. The combination is common — almost a rite of passage in some circles — but that doesn't make it predictable, pleasant, or wise. Cannabis and psilocybin are two of the most-used psychedelics on the planet, and pairing them sits in a strange grey zone between folk wisdom and genuine risk. So let's actually talk about it. This isn't a recipe. It's a closer look at what each substance does, how they interact, and what's worth knowing before you decide whether they belong in the same evening. If you're researching this because you're curious about the broader world of psychedelics and master plants — maybe even considering a structured retreat down the line — the same principle applies: information first, decisions second. The short answer? Cannabis amplifies whatever's already happening. For some people, that means deeper visuals, looser thoughts, and a softer landing on the comedown. For others, it means a perfectly fine mushroom trip suddenly tips into a heart-pounding spiral that lasts an hour and feels like a lifetime. Same drugs, very different experiences — and that variability is exactly the problem. Psilocybin and THC also occupy different categories. Mushrooms are unambiguously psychedelic. Cannabis is harder to pin down — sometimes it acts like a mild hallucinogen, sometimes a depressant, sometimes a stimulant, depending on the strain, the dose, and the person. Stacking an unpredictable drug on top of an already unpredictable one is a recipe for surprises. Some are wonderful. Some are not. Psilocybin converts to psilocin in the body and binds to serotonin 5-HT2A receptors. The net effect is a flood of altered signalling and — this is the part researchers find most interesting — a quieting of the default mode network, the brain circuitry tied to your sense of a continuous, narrating self. When the DMN goes quiet, ego boundaries soften and sensory input gets louder. That's the classic psychedelic state. Cannabis works through a completely different system. THC mimics anandamide, an endogenous cannabinoid, and binds to CB1 receptors throughout the brain and body. CBD takes a subtler path — it slows the breakdown of anandamide and partially blocks CB1 receptors, which is why it can actually take the edge off THC's more anxious moments. Two different mechanisms, two different timelines, one shared bloodstream. Let's get the reassuring part out of the way first: neither psilocybin nor cannabis is physically toxic at recreational doses, and there is no known fatal interaction between the two. You're not going to die. That's not the risk anyone honest is worried about. The actual risk is psychological. Cannabis — especially high-THC, low-CBD cannabis — is surprisingly good at producing anxiety and paranoia in sober people. Now add a psilocybin trip, where your defences against anxious thinking are already lowered, and you have a setup where a small spike of weed-induced unease can balloon into a full panic loop. Racing heart, shortness of breath, that grim certainty that something is deeply wrong. None of it is dangerous in a medical sense. All of it feels awful in the moment. A few specific things worth flagging: If you've decided you want to try it anyway — and plenty of people do, with no drama — the consensus among more experienced users is consistent. Treat the night as a mushroom trip first. The shrooms are the main event. The cannabis is a small, optional accent, not a co-headliner. A reasonable approach looks something like this: Strain choice matters more than people give it credit for. High-CBD strains, or strains with a more balanced THC:CBD ratio, are far less likely to drop you into paranoia. The current trend toward 25%+ THC flower is the exact opposite of what you want on a trip. If you only have access to heavy indica or potent sativa, smaller doses or skipping the weed entirely is the smarter call. This question gets debated endlessly. There's no objectively correct answer, but here's the honest breakdown. Before. Some people smoke a little to ease pre-trip jitters. The risk is that cannabis anxiety becomes the seed of the entire experience, and you spend the next four hours trying to outrun a mood you set yourself. During the peak. Generally the worst option. The peak is already the most overwhelming part. Adding THC at peak is the most reliable way to push a manageable experience into a chaotic one. During the comedown. This is what most experienced users recommend. Two to three hours in, when visuals are softening and you're returning to baseline, a small amount of cannabis can extend the reflective, integrative quality of the experience without overloading your nervous system. This is also when sleep starts to matter, and indica strains can help close out the night. The next day. Maybe the most underrated option. The afterglow from psilocybin can last 24–48 hours, and a low-dose smoke the following evening sometimes brings back gentle echoes of the trip's clarity. No risk of a bad mix, all of the integration benefits. Mixing substances recreationally is a different universe from doing serious psychedelic work — and it's worth being honest about that distinction. People who combine weed and mushrooms at a music festival aren't pursuing the same thing as someone sitting in an ayahuasca ceremony or doing structured psilocybin sessions for depression. Both are valid. They're just different projects with different rules. If your interest in psilocybin is partly therapeutic — addressing depression, addiction, trauma, or just the sense that something in your life is stuck — the recreational mixing question becomes less interesting than the question of set, setting, and support. Most serious facilitators will tell you to leave cannabis out of the picture entirely during intentional work. It muddies the signal. It introduces a variable that has nothing to do with what you're trying to heal. And for people working through addiction specifically, the habit of layering one substance on another is often part of what they're trying to step away from. That doesn't make cannabis bad. It just means context matters. The joint with friends on a Saturday night and the cup of brewed mushroom tea with a trained guide are two different conversations, and treating them as interchangeable is how people end up disappointed in both. Can you mix weed and magic mushrooms? Yes. Should you? It depends entirely on who you are, what you're after, and how well you read your own warning signs. For some people, it's a pleasant amplification — funnier, deeper, more visual. For others, it's the thing that turns a beautiful afternoon into a few hours they'd rather forget. There's no way to know in advance which camp you're in until you try, and the prudent move is to err small: less weed, later in the trip, in a setting you trust. And if reading this has nudged you toward thinking about psilocybin more seriously — as a tool for healing rather than a Saturday-night curiosity — a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. The structured path is a very different animal from the recreational one, and for some people it ends up being the more useful door to walk through.
Types of Psychedelic Mushrooms: A Field Guide to Psilocybin Species and Fly Agaric
Walk into any conversation about psychedelics long enough and someone will say the word “mushrooms” as if it refers to a single thing. It doesn't. The world of psychedelic mushrooms is wider, weirder, and more geographically scattered than most people realize — over 180 known species, several different genera, and at least two completely separate chemical mechanisms producing the trip. If you're researching plant medicine seriously, or considering a psilocybin retreat, knowing what's actually inside the cap matters. This guide walks through the main families of psychedelic mushrooms, what makes them chemically distinct, and why the iconic red-and-white Amanita muscaria is its own strange beast — related to the others mostly in shape, not in spirit. A psychedelic mushroom is any fungus that contains a compound capable of meaningfully shifting perception, mood, or cognition. The vast majority owe their effects to psilocybin — a prodrug that the body quickly converts into psilocin, the actually-active molecule. Psilocin slots into serotonin receptors in the brain (the 5-HT2A site, mostly), and that's where the visuals, the time dilation, and the rearranging of inner furniture come from. People have been eating these mushrooms for a long time. Cave murals in Spain dating back roughly 6,000 years appear to depict Psilocybe hispanica. Desert rock art in Algeria, older still, suggests mushroom use stretching back seven to nine millennia. The Maya consumed Psilocybe cubensis. The Aztecs called certain species teonanácatl — “flesh of the gods.” Whatever you make of that lineage, mushrooms have arguably the longest documented relationship with humans of any psychedelic. The Swiss chemist Albert Hofmann — the same person who first synthesized LSD — isolated psilocybin and psilocin from Psilocybe mexicana in the late 1950s. That moment basically opened the modern scientific chapter on these fungi. Everything since, including the current clinical trials on psilocybin for depression, end-of-life anxiety, and addiction, traces back to that little Mexican mushroom. Most psychedelic mushrooms people will encounter — at a ceremony, at a retreat, in a research paper — belong to the genus Psilocybe. It's the largest grouping, with around 117 species, and contains nearly all the famous names. A few worth knowing: You'll also see Psilocybe baeocystis (bottle caps), Psilocybe pelliculosa, and Psilocybe aztecorum, the latter possibly being one of the original teonanácatl species. Each has its own potency profile, its own habitat, and its own enthusiasts. Psilocybe gets the spotlight, but psilocybin shows up in roughly a dozen other genera. The chemistry is the same — psilocybin, psilocin, sometimes baeocystin — but the mushrooms look and grow differently. Panaeolus is probably the most notable runner-up. Panaeolus cyanescens (sometimes called Copelandia cyanescens, or just “blue meanies”) is significantly more potent than your average cubensis. It's a tropical and subtropical mushroom, common in cattle pasture across Hawaii, parts of Mexico, and Southeast Asia. Panaeolus cinctulus — the banded mottlegill — is less potent but more widely distributed. Other genera include Gymnopilus, Pluteus, Inocybe, Hypholoma, and a handful of less common groupings. Inocybe aeruginascens deserves a quick mention because it's one of only two known natural sources of aeruginascin, a compound that some researchers have informally called “the CBD of magic mushrooms” for its apparent ability to soften the rougher edges of a trip. Whether that holds up under proper clinical scrutiny is still an open question. The point isn't that you need to memorize all this. The point is that “magic mushrooms” isn't a single substance — it's a category that includes everything from the laboratory-bred Penis Envy to obscure species growing on rotting logs in northern Spain. And then there's Amanita muscaria. The red cap with white dots. The mushroom in every video game, fairy tale, and Mario world. It is psychoactive — but it is not a psilocybin mushroom, and lumping it in with the others is a category error worth correcting. Amanita muscaria belongs to a genus that includes some of the most toxic fungi on Earth. The Amanitas as a group are responsible for the overwhelming majority of fatal mushroom poisonings worldwide. Fly agaric itself is technically classed as poisonous, though actual deaths from it are vanishingly rare and almost always involve massive overdoses or confusion with a more dangerous relative. The active compounds in fly agaric are muscimol and ibotenic acid, with smaller amounts of muscazone and muscarine. When you eat the mushroom, your body converts ibotenic acid into muscimol — the more potent of the two. Crucially, muscimol doesn't touch serotonin receptors at all. It acts on the GABA system, which is roughly the brain's brake pedal. That's why an Amanita experience is described so differently from a psilocybin one: less kaleidoscopic, more dreamlike, often sedating, sometimes outright dissociative. Effects can include: Indigenous shamans across Siberia — particularly the Koryak and Evenki peoples — have used fly agaric ritually for centuries, sometimes consuming it directly, sometimes drinking the urine of someone who already had (muscimol passes through the body largely intact, which is grim but pharmacologically interesting). It is, in every meaningful sense, a different medicine than psilocybin. If you're considering a retreat or ceremony, the practical question isn't usually “which species?” — most legitimate facilitators are working with Psilocybe cubensis or Psilocybe tampanensis truffles, and that's a known, well-mapped experience. The more useful questions are about dose, setting, screening, and integration support. A few things genuinely worth asking before you commit: The fly agaric question is a different conversation. Amanita muscaria retreats exist, but they're rarer, less standardized, and worth approaching with extra caution. The compound profile is genuinely different and the experience can be physically rougher. It's not for first-timers. One thing that gets lost in the listicle-style coverage of psychedelic mushrooms: these are old organisms with old relationships to people. The species names matter less than the relationship you build with whichever one you sit with. Curiosity is good. Reverence is better. A bit of fear, in the proper sense — taking the thing seriously — is probably the most underrated ingredient in a good psychedelic experience. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whichever direction you go, the mushroom you choose deserves the same care you'd give any teacher worth the name.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Why Big Healthcare Money Is Quietly Backing Psychedelic Medicine
Something interesting has been happening in the back rooms of biotech finance, and most people booking a retreat in Peru next month have no idea. The same venture capital firms that bankrolled Moderna and Novavax are now writing checks to companies developing psychedelics into prescription medicines. That shift matters — not because Wall Street's blessing makes plant medicine more legitimate (it doesn't), but because it changes what's coming next. If you're researching ayahuasca, psilocybin, or any other psychedelic path for depression, addiction, or trauma, the story of who's funding what gives you a useful map. It tells you which compounds will reach clinics first, which retreats will face new competition from medical models, and which therapies remain — for now — only available outside the regulated system. Let's walk through what's actually happening. A few years ago, investing in psychedelic research looked like a hobby for eccentric philanthropists and crypto guys with a microdosing habit. That's no longer the case. A wave of specialist funds emerged first — small firms built specifically around psychedelic startups — and they did the unglamorous work of pushing early compounds through preclinical hurdles. They proved the science wasn't a joke. Now the bigger fish have arrived. Established healthcare venture capital firms with billion-dollar funds have started putting real money behind psychedelic biotech. These are the firms that fund late-stage clinical trials, the kind of trials that cost tens of millions and involve hundreds of patients across multiple sites. Without that capital, no psychedelic drug ever reaches an FDA approval. With it, the timeline shortens dramatically. The shift signals something subtle but important: psychedelics are no longer being treated as a curiosity. They're being treated as a drug development pipeline, with all the rigor and skepticism that implies. For the retreat-seeker, that's a double-edged thing. More research means better safety data and clearer answers about who benefits. It also means a medicalized future where some of these compounds become tightly regulated prescriptions rather than ceremonial sacraments. A handful of mainstream healthcare investors have made multiple bets in the space. Boston-based RA Capital — better known for funding vaccine makers — has backed at least three psychedelic-focused companies, including GH Research, Cybin, and Delix Therapeutics. All three are chasing mood disorders: depression, anxiety, and the stuck states that talk therapy and SSRIs can't always touch. Catalio Capital, a younger biotech-focused firm, has held positions in Atai Life Sciences and Compass Pathways through both their private and public stages. OrbiMed, a New York firm with stakes in more than eighty life-sciences startups, has put money behind Awakn — which is studying ketamine and MDMA for alcohol-use disorder — and Cybin, which is working on psilocybin and DMT-based compounds. Soleus Capital has stakes in Compass Pathways and Field Trip. If you've been following addiction recovery research, the Awakn investment is the one to circle. MDMA and ketamine for alcohol-use disorder is the kind of clinical work that could legitimately reshape how we treat addiction in the next decade. And it's being funded not by ideologues but by people who measure outcomes in spreadsheets. One company has attracted more healthcare-VC attention than the rest: GH Research, a Dublin-based outfit developing a treatment for treatment-resistant depression based on 5-MeO-DMT. That's the psychoactive compound traditionally extracted from the secretions of the Sonoran Desert toad — though clinical versions are synthesized, not harvested from amphibians. Why the unusual amount of investor enthusiasm? Two reasons, according to analysts who cover the company. First, the experience itself is short — typically under thirty minutes rather than the six-to-eight-hour marathon of a psilocybin session or the all-night ayahuasca journey. From a clinic-operations standpoint, that's enormous. Fewer staff hours per patient, faster turnaround, easier to scale. Second, the founders came in with substantial biotech credibility, which matters more than people in the plant-medicine world tend to admit. For readers who've sat with 5-MeO-DMT in ceremony, this medicalization can feel strange. The traditional context — drums, prayers, a guide who's worked with the medicine for years — gets stripped away in favor of a clinical room and a structured protocol. Whether that's a loss or simply a different valid container is one of the genuine debates in this field right now. Here's the practical takeaway. The medical pipeline and the retreat world are running on parallel tracks, and they will eventually intersect. Some predictions worth holding loosely: If your interest is in classic ayahuasca ceremony with experienced curanderos, the venture capital story barely touches your decision. Those traditions exist in a different ecosystem and will continue to. If your interest is psilocybin or MDMA for a specific clinical issue like depression or PTSD, you may want to weigh whether to seek a retreat now or wait for regulated options that could appear in the next handful of years. Retreats and clinics offer genuinely different things, and neither is universally better. A reputable plant-medicine retreat gives you traditional context, longer integration time, group ceremony, dietary preparation, and access to compounds and combinations that no clinic will ever offer. The costs are typically lower than medicalized therapy will be, though they're not cheap. A future FDA-approved psilocybin treatment will offer insurance coverage potentially, standardized dosing, screened therapists with malpractice insurance, and a legal framework that removes the risk of arrest or job consequences. What it likely won't offer is the cultural depth, the community, or the multi-day arc that lets the medicine work at the pace it wants to work. Both models have their failures too. Retreats vary wildly in quality, and there are operations out there with weak screening, undertrained facilitators, and no real integration support. Clinical models will have their own problems — the same brittleness that makes psychiatry frustrating for many people who go looking for help isn't going to vanish just because the molecule changes. Tracking who funds what is one of the more boring ways to predict where psychedelic medicine is heading, and one of the most reliable. When mainstream healthcare capital starts moving, regulatory approval tends to follow within a few years. The compounds with the most investor interest right now — psilocybin, MDMA, 5-MeO-DMT, ketamine — are the ones most likely to reach clinics first. For someone weighing a retreat decision today, the practical question isn't whether psychedelics work. The research increasingly suggests they do, for specific conditions, for specific people, under the right conditions. The question is whether the ceremonial route or the eventual clinical route fits your situation better — and that's a personal calculation involving your condition, your resources, your tolerance for uncertainty, and your relationship to ritual and tradition. If you want to explore what's currently available in the ceremonial and retreat world while the clinical options continue to develop, a curated selection of plant-medicine and psychedelic retreats can be browsed on our marketplace here. Whatever path you take, take it slowly, ask hard questions of any facilitator or clinician, and remember that the medicine is only part of the work.
What a Kambo Ceremony Actually Feels Like: One Woman's First Time with the Frog
The first time I heard someone describe kambo, they called it “twenty minutes of dying, then you feel reborn.” That's the kind of sentence that either makes you walk away or quietly book a flight. If you've found your way to this article, you probably already know which camp you're in — you're curious about plant medicine, you've maybe done ayahuasca or are circling around it, and now you're wondering whether this strange frog-secretion ritual is something worth sitting for. This is one person's account of a first kambo ceremony, told honestly, with the gross bits left in. It's not a sales pitch. It's not a warning either. It's the kind of description I wish I'd had before I sat down on the floor, half-naked, and let a stranger burn my back. Kambo is the dried secretion of the giant monkey frog — Phyllomedusa bicolor — a bright green tree frog found across the western Amazon. Indigenous groups including the Matsés, Katukina, and Yawanawá have used it for generations as a hunting medicine, an immune tonic, and a way to clear what they call panema: bad luck, heaviness, stuck energy. The frog isn't killed. A practitioner mimics its call, the frog comes down, a small amount of secretion is scraped from its back, and it's released. The dried film is then reactivated with saliva or water and applied to small burns on the skin. What happens next is the part nobody can quite prepare you for. The peptides in the secretion — there are dozens of them, some of which have legitimate medical research behind them — flood your system within seconds. Your face flushes hot. Your heart pounds. Your blood pressure drops, then spikes. You may feel your tongue swell, your stomach turn, your skin tingle. Within a few minutes, most people purge — vomiting up the two or three liters of water they were asked to drink beforehand. The whole acute phase lasts twenty to forty minutes. Then, for many people, comes a strange lightness that's difficult to describe and even harder to forget. I'd been having a rough run of months. A long relationship had ended. Friendships were thinning out in that quiet way they do when you're shifting. I was raising kids, rebuilding a small business, and pretending I was fine. The standard self-care toolkit — lemon water, journaling, the occasional yin yoga class — had stopped touching it. A friend mentioned a practitioner staying at his house. I felt the pull. I've learned to trust that pull, even when I can't justify it. With ayahuasca, the call had been almost nagging for years before I finally went. With kambo, it was softer — more of a tap on the shoulder than a shout. I arrived on a Monday morning, fasted since the night before. The house sat behind a row of others in a quiet northern village, surrounded by flat green fields. My friend hugged me at the door and I burst into tears for no obvious reason. He just held on, smiled, said “good that you came,” and led me inside. Before any kambo touches your skin, you drink. A lot. At least a liter and a half, usually closer to three. Lukewarm, because cold water on an empty stomach during this process is its own kind of cruelty. The water isn't for hydration. It's the vehicle for the purge. When the secretion hits and the body decides to expel everything, you want something in there to expel. People who don't drink enough tend to dry-heave for an uncomfortably long time. People who drink enough release a clean wave and feel better fast. I was about two liters in when the practitioner walked in. I'd been picturing an older man with weathered hands, speaking Portuguese or Spanish I'd struggle to follow. Instead, a tattooed European in his late thirties walked through the door, whistling a tune I didn't recognize, smiled at me like we'd known each other for years, and pulled me into a hug. The cliché of what a healer “should” look like fell apart in about four seconds. That, I'd later realize, is part of the lesson. The application itself is quick and surprisingly low-drama. A thin stick is heated in a candle flame until it glows. The practitioner uses it to make small superficial burns — usually two or three on the upper arm for a first-timer, sometimes on the back, shoulders, or legs depending on what they read in your body. The burns sting briefly. They're not deep. They leave small round scars that fade over months, which many practitioners and participants think of as a kind of map. The reactivated kambo paste is dabbed onto the open burns. Within ten to twenty seconds, the medicine arrives. For me it came as heat — a flooding warmth that started in my belly and rose to my face. My lips felt thick. My pulse drummed in my ears. My head felt swollen, like I'd descended too fast in an aeroplane. What surprised me most was that I could stay present with it. I'd been bracing for terror. Instead I found something closer to intense observation. I'd given birth three times without medication. I'd sat in ayahuasca ceremonies. My body, it turned out, knew how to ride a wave of discomfort. I breathed. I noticed. I waited. The practitioner whistled the whole time — a melodic, repetitive song that genuinely did seem to hold the room. He squeezed my shoulders, pressed deep into points on my stomach that other bodyworkers had always zeroed in on, sprinkled water scented with something herbal across my skin. When the third burn went on, the nausea rose fast. I leaned over the bucket and let it go. A startling volume of water came out. Then I was empty, and quiet, and the heat in my head began to recede. This is the question that matters most if you're reading this and thinking about booking something. Kambo is generally well-tolerated by healthy adults, but it is not without risk, and the risks are not theoretical. The single most important variable is who's holding the space. Ask about training lineage. Ask how many ceremonies they've facilitated. Ask what they screen for. Ask what happens if something goes wrong — is there a phone signal, a vehicle, a plan? A practitioner who waves these questions off is one to walk away from. People come to kambo for a lot of reasons. Chronic inflammation. Depression that won't lift. Lyme disease and other lingering infections. Brain fog after a hard year. A sense that something is stuck and won't move. The research on the peptides — particularly dermorphin, deltorphin, and phyllocaerulein — is genuinely interesting, but the clinical picture is still thin. The traditional framing of kambo as a cleansing and clearing medicine has held up better than most of us cynical Westerners expected. What kambo isn't: a magic eraser. It won't undo years of trauma in a single session. It won't replace therapy, integration, or the slower work of changing your life. People who treat it as a quick fix tend to come away disappointed. People who treat it as one tool in a wider practice tend to come away grateful. For those weighing whether plant medicine of any kind might help with addiction, depression, or stuck patterns, kambo is often a useful early step — physically intense but shorter and less psychologically disorienting than ayahuasca, ibogaine, or psilocybin. Some people use it as preparation before a bigger ceremony. Others find it's enough on its own. Within an hour of the ceremony ending I was eating fruit, laughing about something inconsequential, and feeling lighter than I had in months. Not euphoric — that word always sounds like marketing. Just lighter. The static in my head had quieted. The grief I'd been carrying was still there, but it had room to breathe around it. That clarity held for about a week before normal life began to reassert itself, which is roughly what experienced participants had told me to expect. Kambo isn't subtle, but its gifts are. You don't get a personality transplant. You get a window. What you do with the window is the actual work. If you've read this far and something in you is still leaning forward, that's worth paying attention to. Curated kambo ceremonies and broader plant-medicine retreats can be browsed on our marketplace here, with practitioner backgrounds and screening protocols laid out so you can make a clear-eyed choice. Whatever you decide, do the boring due diligence first — the frog will still be there when you're ready.
Kambo Therapy: What to Really Expect From the Frog Medicine Ceremony
The first thing people tell you about kambo is the purge. The second thing they tell you, usually about ten minutes later, is that it was somehow worth it. Sit with anyone who's done a serious round of plant medicine work and kambo comes up — sometimes whispered, sometimes laughed about, almost always with a strange affection for an experience that, on paper, sounds horrible. So what is it actually? Kambo is the secretion of the giant monkey frog, Phyllomedusa bicolor, native to the Amazon basin. For centuries the Matsés, Katukina, Yawanawá and other indigenous peoples have used it as a hunting medicine and a cleanse — a way to clear what they call panema, a kind of heavy energetic fog that settles on a person and dulls their luck, focus, and vitality. In the last decade or so it's leaked out of the rainforest and into wellness centers, ayahuasca retreats, and urban living rooms from Berlin to Bali. Whether that's a good thing depends a lot on who's holding the stick. The mechanics are simple and a little startling. A practitioner uses a smoldering vine to burn small superficial dots — usually three to seven of them — into the top layer of skin, most often on the shoulder for men or the lower leg for women. These are called gates. The dried frog secretion is mixed with water into little dots of paste, and those dots are pressed onto the open points. The medicine enters directly through the lymphatic system rather than the stomach. Within thirty seconds, things start. A flush of heat moves up the chest and face. The heart rate climbs. Some people describe a tight band around the head, others a swelling sensation in the throat or tongue. Then comes the part everyone warns you about: the purge. You drink a couple of liters of water beforehand, and your body finds a fairly emphatic way to get rid of it. Most of the intense phase is over in fifteen to thirty minutes. The medicine is then wiped off the gates, and you rest. It's short. That's the thing nobody quite prepares you for. Compared to an ayahuasca ceremony — six, seven, sometimes nine hours of inner weather — kambo is a sprint. You're back on your feet and quietly eating soup within an hour or two. The science here is more interesting than the marketing usually lets on. Kambo secretion contains a cocktail of bioactive peptides — dermorphins, deltorphins, phyllomedusin, phyllocaerulein, sauvagine, and others. Some of these are powerful opioid agonists (dermorphin is roughly forty times stronger than morphine in lab assays). Others act on smooth muscle, blood pressure, and the gut. A few have shown interesting activity in early-stage research on infections and inflammation. What does that mean for you, on the mat? A few things seem reasonably well-established from observation: Beyond that, claims get fuzzier. You'll hear that kambo resets the immune system, kills cancer cells, treats Lyme disease, and rewrites your karma. Some of these are plausible avenues for future research. None of them are proven. A serious practitioner will tell you that honestly. A salesperson won't. This is where I want to slow down, because the casual framing kambo sometimes gets in wellness spaces underplays the real stuff. Kambo is not a gentle herbal infusion. It's a potent peptide cocktail that puts measurable strain on the cardiovascular system. There have been deaths. Not many, but enough. The biggest danger is hyponatremia — water intoxication. Because the ritual involves drinking a large volume of water and then purging, the sodium balance in the blood can crash, particularly if a participant keeps drinking more water than the practitioner advises. This can trigger seizures and, in rare cases, be fatal. A good facilitator measures water carefully and stops you from over-drinking. A careless one hands you a bucket and walks away. People who should not do kambo at all (or should only do so under medical supervision): If your practitioner doesn't take a thorough health intake before agreeing to work with you — blood pressure, medications, mental health history, the lot — walk away. That alone is the single biggest filter between a safe session and a dangerous one. Now, the part that's harder to put on a lab report. People come out of kambo describing things that sound a lot like what you hear after a psychedelic session, even though kambo isn't classically psychedelic. There's clarity. A sense of weight lifting. Sometimes a quiet emotional release — tears that arrive without a clear story attached, or a sudden recognition of something you've been carrying. Why? Honest answer: nobody fully knows. Part of it is probably the intensity of the experience itself — pushing your body through something that hard tends to shake loose whatever's sitting on the surface. Part of it may be the opioid peptides briefly flooding the system. Part of it is almost certainly the ceremonial frame — the intention, the silence, the witnessing of your own purge as something more than just being sick. People who use kambo regularly often pair it with other plant medicine work. It's common to see it offered at the start of an ayahuasca retreat as a kind of clearing, or in between ceremonies to break a stuck pattern. Some folks use it on its own as a once-or-twice-a-year reset. I've talked with a handful of people in addiction recovery who swear by it — not as a cure, but as something that gives them a clearer line of sight on the cravings and stories underneath. The evidence there is anecdotal but consistent enough to be worth noticing. This is where most of the difference between a transformative session and a regrettable one lives. The kambo space is largely unregulated, which means the floor is very low. A weekend course exists. Anyone can call themselves a practitioner. So you have to do the filtering yourself. Questions worth asking before you book: A practitioner who answers these clearly and unhurriedly is probably someone you can trust. One who deflects, gets defensive, or leans on mystical language to dodge the practical questions is not. Kambo is having a moment, and the reasons are worth naming honestly. There's a real hunger right now for embodied, non-pharmaceutical approaches to mental and physical health — partly because conventional options have failed a lot of people, partly because the broader psychedelic renaissance has made plant medicine feel legitimate again. Kambo slots into that opening. It's short, it's intense, it produces visible effects, and it has the kind of indigenous lineage that lends it weight. It also fits the rhythm of modern life in a way ayahuasca doesn't quite. You can do kambo on a Saturday morning and be functional by evening. You can fold it into a longer retreat without it eating the whole week. For people curious about plant medicine but not ready for a multi-day journey, it can feel like a manageable doorway. None of that makes it a casual thing. The ceremonies that work best are the ones held with care — small groups, an experienced practitioner, a clear container, and time afterward to rest and integrate. The ones that go badly tend to be rushed, oversold, or run by someone who learned the ritual from a YouTube video. Read more than one source. Talk to people who've done it. Get honest with yourself about your health history and whether this is the right tool for what you're actually looking for. Kambo isn't a magic bullet for depression, addiction, or trauma — and any practitioner who tells you it is should make you nervous. What it can be, in the right hands, is one useful instrument in a longer process of paying attention to your body and your patterns. If something here resonates and you'd like to explore it further, a selection of vetted kambo and plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The right ceremony, with the right people, is worth waiting for.
Peyote Demystified: Effects, History, and What a Ceremony Actually Looks Like
Peyote is one of those plant medicines people whisper about but rarely understand. It’s older than most religions, smaller than your palm, and contains a compound — mescaline — that has shaped indigenous spiritual life across the deserts of North America for thousands of years. If you’ve been circling the broader world of psychedelics and master plants, peyote keeps surfacing as a name that carries weight. Let’s actually unpack what it is, where it comes from, and what you should know before considering a ceremony. This isn’t a sales pitch and it isn’t a romantic travelogue. It’s the kind of overview I wish someone had handed me years ago, when I first started asking real questions about plant medicine for addiction, depression, and the stuck patterns that bring most people to these traditions in the first place. Peyote (Lophophora williamsii) is a small, spineless, button-shaped cactus that grows in the limestone soils of northern Mexico and a thin slice of southwestern Texas. It looks unremarkable — squat, blue-green, sometimes crowned with a pale pink flower. You could walk past one in the Chihuahuan Desert and not notice it. That modesty is part of why traditional cultures regard it as something hidden, something you have to be ready to see. Its active compound is mescaline, a phenethylamine psychedelic that also occurs in the San Pedro and Peruvian Torch cacti. Fresh peyote contains roughly 0.4% mescaline; dried buttons concentrate that figure to between 3 and 6 percent. The cactus also contains a soup of other alkaloids, which is why people who’ve taken both peyote and pure mescaline often report the two experiences feel meaningfully different — peyote tends to be earthier, heavier, more body-based. One thing worth sitting with: peyote grows astonishingly slowly. A wild plant can take over a decade to reach maturity. This single fact reshapes everything else about how it should be approached — ethically, ecologically, and ceremonially. Archaeological finds along the Rio Grande place peyote use as far back as 3,700 BC. That is not a typo. Humans have been in relationship with this cactus for nearly six thousand years. The Aztecs called it peyōtl — roughly, “the thing that glimmers” — and treated it as a divine messenger, a way to speak with the gods. Spanish missionaries arriving in the 1500s documented its use with a mixture of fascination and alarm, and predictably tried to suppress it. Western science came to peyote late and clumsily. A Dallas physician published an account of his own self-experimentation in 1887. A few years later, the Comanche chief Quanah Parker sent a large supply of dried buttons to an ethnologist at the Smithsonian, who passed samples to William James and other early American psychologists. The cactus was formally classified in 1894, and its first scientific trial appeared in a medical journal the following year. None of that, of course, is where the real story lives. The real story lives with the Huichol (Wixáritari) of the Sierra Madre Occidental, who still make an annual pilgrimage of roughly 300 miles to Wirikuta, the sacred desert where the peyote grows. And with the members of the Native American Church, who carry an unbroken ceremonial relationship with this plant into the present day. The crown of the cactus — the “button” — is sliced off and dried. From there it’s either chewed (intensely bitter, often followed by nausea) or simmered into a tea. The nausea is not a bug; in many traditions it’s considered part of the purification. The plant is asking something of you before it shows you anything. Among the Huichol, peyote ceremonies involve singing, weeping, prayer, and communication with ancestors and deities. The plant isn’t recreational and isn’t framed as therapy in the clinical sense — it’s a sacrament, woven into a worldview where the visible and invisible worlds are constantly in conversation. The Native American Church (NAC), which formed in the late 19th century, blends indigenous spirituality with Christian elements in varying proportions depending on the branch. Their all-night ceremonies take place in a tipi, led by a peyote “chief,” and include prayer, song, contemplation, and the sacramental eating of the buttons. For many members, peyote is the medium through which the Creator becomes audible. Peyote is a long one. Effects typically last between 8 and 16 hours, putting it in the same endurance category as LSD or ibogaine. That length is part of why ceremonies run all night — the medicine sets its own clock. Onset is gradual: an hour or so of building physical heaviness, often with that famous wave of nausea, then the perceptual shifts begin. Common physical effects include: Cognitive and emotional effects can be substantial: enhanced creativity, deep introspection, an altered sense of self, vivid memory work, music that suddenly feels structural rather than decorative, and — for some — moments described as self-realization. The perceptual layer brings visual patterning, depth and color shifts, and at higher doses, full visionary content. As with every psychedelic, dose, set, and setting shape almost everything. A button taken in someone’s apartment is not the same medicine as a button taken in a tipi with a fire and a song carrier and people who’ve been holding ceremony for thirty years. Legal status is layered. In the United States, peyote is a Schedule I substance — except for documented members of the Native American Church, who are protected under the American Indian Religious Freedom Act amendments. In Mexico, peyote is protected as part of indigenous cultural heritage, and harvesting outside traditional contexts is restricted. In Canada, peyote occupies a strange middle ground: mescaline is controlled, but the cactus itself is exempt. The ethical question is louder than the legal one. Wild peyote populations are in trouble. Overharvesting, illegal poaching, and habitat loss in the Texas-Mexico borderlands have pushed the plant into ecological stress. Many indigenous leaders have publicly asked non-Native seekers to choose other mescaline-containing cacti — San Pedro and Peruvian Torch, both of which grow much faster and are cultivated sustainably in South America — rather than putting more pressure on a sacred plant that takes ten years to grow back. That’s a request worth honoring. If your curiosity is about mescaline as a master plant, San Pedro ceremonies in the Andes offer that doorway without participating in the decline of a sacred ecosystem. Here’s the honest version. People come to plant medicine for real reasons — addiction, depression, grief, trauma, a feeling of being unmoored from their own life. Mescaline-containing cacti have a long track record of helping with exactly those struggles, but they aren’t a vending machine. The experience is long, physically demanding, and emotionally unpredictable. Preparation matters. Integration matters more. A few things to weigh if you’re seriously considering it: Peyote isn’t a shortcut, and it isn’t a souvenir. It’s a plant a lot of people have given their lives to protect. Approached with that kind of seriousness, mescaline medicines can be genuinely transformative for the patterns that brought you to this article in the first place. If you want to explore this path further, a range of San Pedro and mescaline-tradition retreats — most of them sustainable, ethically run, and welcoming to non-Native seekers — can be browsed on our marketplace here. Take your time choosing. The plant has been waiting six thousand years; another week of careful research won’t hurt.
Iboga Flood Dose: What an Ibogaine Ceremony Actually Feels Like
The first time someone described an iboga flood dose to me, they used the word “surgery.” Not metaphorically — they meant it the way you’d talk about a procedure you booked, prepped for, and recovered from. That framing stuck with me. Among the plant medicines drawing serious attention right now, iboga sits in a category of its own: slower, heavier, and more clinical than most of its psychedelic cousins. It’s also the one most often discussed in the same breath as addiction, which is why people end up researching it at 2 a.m. after years of trying everything else. If you’re reading this, you’re probably weighing whether to book a ceremony, or trying to understand what a friend went through, or quietly wondering whether iboga could break a pattern that won’t budge. Fair. Let’s talk honestly about what a flood dose actually involves — the hours, the sensations, the risks, and what people tend to carry home with them. Iboga refers to the root bark of Tabernanthe iboga, a shrub native to Central Africa, used ceremonially by the Bwiti for generations. Ibogaine is the principal alkaloid extracted from that bark — the molecule most often used in clinical and underground addiction-interruption settings. A “flood dose” means a single, large oral dose, calibrated to body weight, intended to produce a full immersive experience lasting roughly 24 to 36 hours. This isn't microdosing. This isn't a weekend of mushrooms. It's a long, demanding inner sit. Doses are typically measured in milligrams per kilogram of body weight, and reputable providers will run cardiac screening, liver panels, and a medical intake before they hand you anything. Iboga and ibogaine carry real cardiac risks — they can affect heart rhythm in ways that have killed people who weren't screened. Anyone offering a flood dose without an EKG and a medic present is not running a safe operation. That's not me being cautious. That's the floor. Most folks who pursue a flood dose fall into one of two camps. The first is people trying to interrupt opioid, alcohol, or stimulant addiction — iboga's reputation as an addiction-interruption tool is what built its modern legend, and clinical observation backs up at least part of the story. The second is people drawn to deep psychological work: trauma, grief, identity questions, a sense of being stuck in a story they can no longer narrate their way out of. Iboga is sometimes called a “master teacher” among master plants, and the experience does have a teacherly quality — direct, unsentimental, sometimes uncomfortably specific. You'll usually take the dose in stages — a test dose first, then the main amount once the team confirms you're tolerating it. The onset is gradual. Within the first hour, most people describe a buzzing or vibrating sensation, sometimes auditory — a high-pitched hum that locks in and stays for hours. Movement becomes difficult. Coordination drops. You'll likely be asked to lie down and stay there, because trying to walk to the bathroom feels like piloting a rowboat in heavy weather. Nausea is part of the package. Some people purge, some don't. The body load is real and not particularly poetic — your limbs feel heavy, your stomach unsettled, your sense of physical orientation scrambled. This is not the giggly, melty quality of psilocybin. It's closer to a fever dream you stay conscious through. Knowing this in advance helps. People who expect bliss are surprised. People who expect work are not. Once the body settles into its strange new gravity, the visual material starts. Eyes closed, most people report long internal films — autobiographical reels, ancestral imagery, encounters with figures that feel distinct from the self. The classic iboga description is of being shown your life from the outside, often in chronological order, with attention paid to moments you'd forgotten or filed away. Some people describe being “interviewed” by a presence. Others describe a kind of library, or a forest, or a long road. The content is intensely personal. Two people in the same room will have completely unrelated journeys. What they tend to share is the texture: clear-eyed, unhurried, and oddly factual. Iboga rarely flatters. It tends to show you things you already half-knew but had been working hard to ignore. This is the stretch most retreat preparations underplay. Around the 8-to-12 hour mark, the visions soften, but the experience isn't over — not even close. What follows is sometimes called the “gray zone” or the cognitive phase: hours of lying awake with your thoughts moving slowly, the body still heavy, sleep impossible. You'll review the visions. You'll reconsider relationships. You'll plan things you've been avoiding planning. Time stretches in a way that's hard to describe to someone who hasn't been there. Some people find this phase harder than the peak. There's no dramatic content to hold onto, just an extended encounter with your own mind in an altered, lucid state. Facilitators usually check in quietly, offer water, adjust the room, and otherwise leave you to it. The work is internal. Trying to socialize through it tends to feel wrong. By hour 30 or so, most people can sit up, sip broth, and start the slow return. The first night of real sleep usually comes about 36 to 48 hours after the dose, and it tends to be unusually deep. From there, the integration window opens — the period that actually determines whether the ceremony changes anything in your life. For people working on addiction, the first week is often striking. Cravings that have been constant for years can drop to near-zero. This window is real, but it's a window, not a cure. People who treat the post-ceremony weeks as a victory lap tend to relapse. People who treat them as a rare opening — a chance to build new structures, get into therapy, repair relationships, change their environment — tend to do dramatically better. I've come to think of the flood dose itself as maybe 20% of the work. The rest is what happens in the months afterward. Iboga shows you things; it doesn't install them. Without follow-up — talk therapy, somatic work, community, sometimes medication — the insights blur and fade like dreams you didn't write down. Reputable retreats build this in: post-ceremony integration calls, referrals to integration specialists, sometimes a structured aftercare program. If a provider doesn't mention integration in their materials, that's a yellow flag. The medicine works in conjunction with what you do with it. Nobody who's spent serious time around iboga will tell you otherwise. The iboga and ibogaine world is unevenly regulated. Some centers are excellent — medically supervised, ethically run, transparent about outcomes and risks. Others are not. A few questions to ask before you wire any money: If the answers feel vague, evasive, or annoyed, that's information. A serious operation will welcome these questions because they ask them of themselves. Cost varies widely — anywhere from a few thousand to well into five figures depending on country, length, and medical infrastructure. Cheaper isn't always worse, and pricier isn't always safer, but extremely low prices usually mean something has been cut, and what gets cut is almost always medical oversight. Iboga isn't for everyone, and it isn't a first-line option for most situations. If you've never worked with plant medicine before, ayahuasca or psilocybin are gentler doorways. If you're on SSRIs, certain heart medications, or have a cardiac condition, iboga may be contraindicated entirely — non-negotiable, no workaround. If you're in active crisis without support around you, this is not the moment. If you're curious but uncertain, talk to people who've done it. Read the harder accounts, not just the triumphant ones. That said, for the right person at the right time, a flood dose can be one of the most clarifying experiences available. It tends to attract people who have already tried the conventional routes and want something that meets them at the depth their situation actually requires. If that's you, take your time. Choose carefully. For readers wanting to explore options further, a range of vetted ibogaine and iboga retreats can be browsed on our marketplace here. The medicine will still be there next month. Better to arrive prepared than to arrive fast.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
